Monograph
L01XD03 - Methyl Aminolevulinate |
Not porphyrinogenic |
NP |
Rationale
Insignificant systemic exposure. No phototoxic effects outside the skin application site.
Chemical description
Methyl aminolevulinate is a linear metylated five carbon molecule. After tissue demetylation it constitutes the initial precursor in porphyrin biosynthesis.
Therapeutic characteristics
Methyl aminolevulinate hydrochloride is a derivative of 5-aminolevulinic acid that is applied topically for the treatment of non-hyperkeratotic, non-pigmented actinic keratoses of the face or scalp, and in the treatment of superficial and/or nodular basal cell carcinoma.
Hepatic exposure
Not significant.
Metabolism and pharmacokinetics
Metabolized in situ to phototoxic porphyrins. In-vitro studies of dermal absorption found that the mean cumulative absorption of methyl aminolevulinate through healthy human skin after 24 hours was 0.26% of a dose.
Similar drugs
References
| # | Citation details | PMID |
|---|---|---|
| * | Drug reference publications | |
| 1. | Sweetman SC, editor. Martindale: The complete drug reference. Methyl aminolevulinate Hydrochlorid. Pharmaceutical Press 2009.
|
|
| * | Summary of Product Characteristics | |
| 2. | Norwegian medicines agency. Summary of Product Characteristics (SPC). Metvix.
|
|
Tradenames
This list comprises raw data collected from different countries.
In some cases, a more comprehensive list of available drug packages is included.
Consequently, very similar terms may therefore appear multiple times.
Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Metvix 
Metvix 
Luxera · Metvix 
Metvix 
Metvix 
Metvix 
Metvix 
Metvix 
Metvix
© NAPOS 2025